Cargando…

Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence

SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Granata, Vincenza, Fusco, Roberta, Setola, Sergio Venanzio, Galdiero, Roberta, Maggialetti, Nicola, Silvestro, Lucrezia, De Bellis, Mario, Di Girolamo, Elena, Grazzini, Giulia, Chiti, Giuditta, Brunese, Maria Chiara, Belli, Andrea, Patrone, Renato, Palaia, Raffaele, Avallone, Antonio, Petrillo, Antonella, Izzo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857317/
https://www.ncbi.nlm.nih.gov/pubmed/36672301
http://dx.doi.org/10.3390/cancers15020351
Descripción
Sumario:SIMPLE SUMMARY: Pancreatic cancer (PC) is one of the deadliest cancers. Its high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. ABSTRACT: Pancreatic cancer (PC) is one of the deadliest cancers, and it is responsible for a number of deaths almost equal to its incidence. The high mortality rate is correlated with several explanations; the main one is the late disease stage at which the majority of patients are diagnosed. Since surgical resection has been recognised as the only curative treatment, a PC diagnosis at the initial stage is believed the main tool to improve survival. Therefore, patient stratification according to familial and genetic risk and the creation of screening protocol by using minimally invasive diagnostic tools would be appropriate. Pancreatic cystic neoplasms (PCNs) are subsets of lesions which deserve special management to avoid overtreatment. The current PC screening programs are based on the annual employment of magnetic resonance imaging with cholangiopancreatography sequences (MR/MRCP) and/or endoscopic ultrasonography (EUS). For patients unfit for MRI, computed tomography (CT) could be proposed, although CT results in lower detection rates, compared to MRI, for small lesions. The actual major limit is the incapacity to detect and characterize the pancreatic intraepithelial neoplasia (PanIN) by EUS and MR/MRCP. The possibility of utilizing artificial intelligence models to evaluate higher-risk patients could favour the diagnosis of these entities, although more data are needed to support the real utility of these applications in the field of screening. For these motives, it would be appropriate to realize screening programs in research settings.